FTWA
VRTX icon

Fifth Third Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Fifth Third Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$918K Sell
1,849
-280
-13% -$124K 0.03% 318
2026
Q1 		$951K Buy
2,129
+415
+24% +$194K 0.03% 282
2025
Q4 		$777K Sell
1,714
-86
-5% -$37.1K 0.03% 298
2025
Q3 		$705K Sell
1,800
-26
-1% -$10.9K 0.03% 301
2025
Q2 		$813K Sell
1,826
-8
-0.4% -$3.69K 0.03% 275
2025
Q1 		$889K Buy
1,834
+607
+49% +$283K 0.05% 240
2024
Q4 		$494K Buy
1,227
+230
+23% +$107K 0.03% 336
2024
Q3 		$464K Buy
997
+489
+96% +$235K 0.03% 327
2024
Q2 		$238K Buy
+508
New +$220K 0.02% 519

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Fifth Third Wealth Advisors's VRTX Position: Q2 2026 in Review

Fifth Third Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, selling an estimated $124K and leaving 1,849 shares worth $918K. The position accounts for 0.03% of the portfolio, ranked #318.

Fifth Third Wealth Advisors first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $951K in Q1 2026. 333 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fifth Third Wealth Advisors held 1,849 shares of Vertex Pharmaceuticals worth $918K as of Q2 2026.
  • Fifth Third Wealth Advisors sold 280 Vertex Pharmaceuticals shares in Q2 2026, an estimated $124K.
  • Vertex Pharmaceuticals made up 0.03% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #318 holding.
  • Fifth Third Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Fifth Third Wealth Advisors's Vertex Pharmaceuticals position peaked at $951K in Q1 2026.
  • 333 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.